Комбинированные методы лечения раннего рака молочной железы. Обзор литературы

Комбинированные методы лечения раннего рака молочной железы. Обзор литературы

Автор: Ахметзянов Ф.Ш., Ахметзянова Р.Ф., Анхимова Л.Е., Горшкова Е.С., Караманян А.В.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Обзоры

Статья в выпуске: 6 т.22, 2023 года.

Бесплатный доступ

Цель исследования - систематический анализ данных о комбинированных методах лечения рака молочной железы при ранних стадиях заболевания с применением послеоперационной, интраоперационной лучевой терапии, имеющихся в современной литературе, и оценка новых подходов к лечению раннего рака молочной железы. Материал и методы. Поиск источников, соответствующих теме обзора, производился в системах Medline, Cochrane Library, Elibrary. Найдено 905 публикаций, посвященных комбинированным методам лечения раннего рака молочной железы, из которых в обзор включены 43 источника.

Ранний рак молочной железы, органосохраняющее лечение, лучевая терапия

Короткий адрес: https://sciup.org/140303553

IDR: 140303553   |   DOI: 10.21294/1814-4861-2023-22-6-172-178

Список литературы Комбинированные методы лечения раннего рака молочной железы. Обзор литературы

  • Bray F., Ferlay J., Laversanne M., Brewster D.H., Gombe Mbalawa C., Kohler B., Piñeros M., Steliarova-Foucher E., Swaminathan R., Antoni S., Soerjomataram I., Forman D. Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer. 2015; 137(9): 2060-71. https://doi.org/10.1002/ijc.29670.
  • Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost' i smertnost'). Pod red. A.D. Kaprina, V.V. Starinskogo, A.O. Shakhzadovoi. M., 2022. 252 s.
  • Khamaza A.A. Otsenka effektivnosti skriningovogo issledovaniya v rannem vyyavlenii raka molochnoi zhelezy. Dostizheniya nauki i obrazovaniya. 2022; 6(86): 90-6.
  • Alieva G. S., Korzhenkova G.P., Kolyadina I.V. Vozmozhnosti mammografii, UZI i MRT v differentsial'noi diagnostike mikrokartsinom razlichnykh biologicheskikh podtipov invazivnogo raka molochnoi zhelezy. Opukholi zhenskoi reproduktivnoi sistemy. 2020; 16(4): 21-34. https://doi.org/10.17650/1994-4098-2020-16-4-12-34.
  • Narzieva D.F., Khodzhaeva D.I. Rak molochnoi zhelezy: sovremennye aspekty diagnostiki. Central Asian Journal of Medical and Natural Science. 2022; 3(4): 99-104.
  • Rasskazova E.A., Zikiryakhodzhaev A.D., Kaprin A.D. Onkoplasticheskie i organosokhranyayushchie rezektsii molochnoi zhelezy pri rake. Meditsinskii alfavit. 2022; 1(5): 42-5. https://doi.org/10.33667/2078-5631-2022-5-42-45.
  • Rozhkova N.I., Prokopenko S.P., Mazo M.L. Diagnostika i lechenie raka molochnoi zhelezy: chto izmenilos' za 20 let. Doktor. Ru. 2018; 2(146): 35-40.
  • Akhmetzyanov F.Sh., Shaikhutdinov N.T., Akhmetzyanova R.F. Sposob pervichnoi plastiki pri rake molochnoi zhelezy. Patent RF № 2171636 C2. Zayavl. 17.05.1999; Opubl. 10.08.2001.
  • Aleksandrova L.M., Kalinina A.M., Ipatov P.V., Gretsova O.P., Starinskii V.V., Kaprin A.D., Boitsov S.A. Vyyavlenie raka molochnoi zhelezy: sostoyanie problemy, puti resheniya. Onkologiya. Zhurnal im. P.A. Gertsena. 2016; 5(2): 34-9. https://doi.org/10.17116/onkolog20165234-39.
  • Lagendijk M., van Maaren M.C., Saadatmand S., Strobbe L.J.A., Poortmans P.M.P., Koppert L.B., Tilanus-Linthorst M.M.A., Siesling S. Breast conserving therapy and mastectomy revisited: Breast cancer-specifc survival and the infuence of prognostic factors in 129, 692 patients. Int J Cancer. 2018; 142(1): 165-75. https://doi.org/10.1002/ijc.31034.
  • Gwark S., Kim H.J., Kim J., Chung I.Y., Kim H.J., Ko B.S., Lee J.W., Son B.H., Ahn S.H., Lee S.B. Survival After Breast-Conserving Surgery Compared with that After Mastectomy in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy. Ann Surg Oncol. 2023; 30(5): 2845-53. https://doi.org/10.1245/s10434-022-12993-0.
  • Manirakiza A., Irakoze L., Manirakiza S. Comparison of Survival Outcomes between Early Breast Cancer Patients who Underwent Mastectomy and Patients Treated by Breast Conserving Therapy: A Meta Analysis. East Afr Health Res J. 2022; 6(1): 1-10. https://doi.org/10.24248/eahrj.v6i1.672.
  • Salim N., Shonus D.Kh., Stolbovoi A.V. Razvitie luchevoi terapii raka molochnoi zhelezy. Onkologiya. Zhurnal im. P.A. Gertsena. 2017; 6(4): 59-65. https://doi.org/10.17116/onkolog20176459-65.
  • Fisher B., Anderson S., Redmond C.K., Wolmark N., Wickerham D.L., Cronin W.M. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med. 1995; 333(22): 1456-61. https://doi.org/10.1056/NEJM199511303332203.
  • Clark R.M., Whelan T., Levine M., Roberts R., Willan A., McCulloch P., Lipa M., Wilkinson R.H., Mahoney L.J. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst. 1996; 88(22): 1659-64. https://doi.org/10.1093/jnci/88.22.1659.
  • van Dongen J.A., Bartelink H., Fentiman I.S., Lerut T., Mignolet F., Olthuis G., van der Schueren E., Sylvester R., Tong D., Winter J., van Zijl K. Randomized clinical trial to assess the value of breast-conserving therapy in Stage I and II breast cancer, EORTC 10801 Trial. Eur J Cancer. 1992; 28 (4-5): 801-5. https://doi.org/10.1016/0959-8049(92)90118-L.
  • Renton S.C., Gazet J.C., Ford H.T., Corbishley C., Sutcliffe R. The importance of the resection margin in conservative surgery for breast cancer. Eur J Surg Oncol. 1996; 22(1): 17-22. https://doi.org/10.1016/s0748-7983-(96)91253-6.
  • Julien J.P., Bijker N., Fentiman I.S., Peterse J.L., Delledonne V., Rouanet P., Avril A., Sylvester R., Mignolet F., Bartelink H., Van Dongen J.A. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: frst results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000; 355(9203): 528-33. https://doi.org/10.1016/s0140-6736(99)06341-2.
  • Hughes K.S., Schnaper L.A., Bellon J.R., Cirrincione C.T., Berry D.A., McCormick B., Muss H.B., Smith B.L., Hudis C.A., Winer E.P., Wood W.C. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term followup of CALGB 9343. J Clin Oncol. 2013; 31(19): 2382-7. https://doi.org/10.1200/JCO.2012.45.2615.
  • Early Breast Cancer Trialists’ Collaborative Group (EBCTCG); Correa C., McGale P., Taylor C., Wang Y., Clarke M., Davies C., Peto R., Bijker N., Solin L., Darby S. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr. 2010; (41):162-77. https://doi.org/10.1093/jncimonographs/lgq039.
  • Chumachenko I.S., Murashko R.A., Keshabyan A.A., Krivorot'ko P.V., Novikov S.N. Rezul'taty organosokhranyayushchego lecheniya raka molochnoi zhelezy s primeneniem intraoperatsionnoi luchevoi terapii. Opukholi zhenskoi reproduktivnoi sistemy. 2021; 17(3): 16-23. https://doi.org/10.17650/1994-4098-2021-17-3-16-23.
  • Kaiser J., Reitsamer R., Kopp P., Gaisberger C., Kopp M., Fischer T., Zehentmayr F., Sedlmayer F., Fastner G. Intraoperative Electron Radiotherapy (IOERT) in the Treatment of Primary Breast Cancer. Breast Care (Basel). 2018; 13(3): 162-7. https://doi.org/10.1159/000489637.
  • Veronesi U., Orecchia R., Maisonneuve P., Viale G., Rotmensz N., Sangalli C., Luini A., Veronesi P., Galimberti V., Zurrida S., Leonardi M.C., Lazzari R., Cattani F., Gentilini O., Intra M., Caldarella P., Ballardini B. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. Lancet Oncol. 2013; 14(13): 1269-77. https://doi.org/10.1016/S1470-2045(13)70497-2.
  • Vaidya J.S., Wenz F., Bulsara M., Tobias J.S., Joseph D.J., Keshtgar M., Flyger H.L., Massarut S., Alvarado M., Saunders C., Eiermann W., Metaxas M., Sperk E., Sütterlin M., Brown D., Esserman L., Roncadin M., Thompson A., Dewar J.A., Holtveg H.M., Pigorsch S., Falzon M., Harris E., Matthews A., Brew-Graves C., Potyka I., Corica T., Williams N.R., Baum M.; TARGIT trialists’ group. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014; 383(9917): 603-13. https://doi.org/10.1016/S0140-6736(13)61950-9. Erratum in: Lancet. 2014; 383(9917): 602.
  • Shah C. Intraoperative Radiation Therapy for Breast Cancer: Are We There Yet? Ann Surg Oncol. 2021; 28(1): 20-21. https://doi.org/10.1245/s10434-020-09356-y.
  • Corsi F., Albasini S., Ciciriello S., Villani L., Truff M., Sevieri M., Sorrentino L. Extensive Intraductal Component in Breast Cancer: What Role in Disease-Free Survival? J Surg Res. 2023; 283: 233-40. https://doi.org/10.1016/j.jss.2022.10.094.
  • Lepomäki M., Karhunen-Enckell U., Tuominen J., Kronqvist P., Oksala N., Murtola T., Roine A. Tumor margins that lead to reoperation in breast cancer: A retrospective register study of 4,489 patients. J Surg Oncol. 2022; 125(4): 577-88. https://doi.org/10.1002/jso.26749.
  • Gage I., Schnitt S.J., Nixon A.J., Silver B., Recht A., Troyan S.L., Eberlein T., Love S.M., Gelman R., Harris J.R., Connolly J.L. Pathologic margin involvement and the risk of recurrence in patients treated with breast-conserving therapy. Cancer. 1996; 78(9): 1921-8. https://doi.org/10.1002/(sici)1097-0142(19961101)78:93.0.co;2-#.
  • Smitt M.C., Nowels K.W., Zdeblick M.J., Jeffrey S., Carlson R.W., Stockdale F.E., Goffnet D.R. The importance of the lumpectomy surgical margin status in long-term results of breast conservation. Cancer. 1995; 76(2): 259-67. https://doi.org/10.1002/1097-0142(19950715)76:23.0.co;2-2.
  • Pezner R.D., Wagman L.D., Ben-Ezra J., Odom-Maryon T. Breast conservation therapy: local tumor control in patients with pathologically clear margins who receive 5000 cGy breast irradiation without local boost. Breast Cancer Res Treat. 1994; 32(3): 261-7. https://doi.org/10.1007/BF00666003.
  • Romestaing P., Lehingue Y., Carrie C., Coquard R., Montbarbon X., Ardiet J.M., Mamelle N., Gérard J.P. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol. 1997; 15(3): 963-8. https://doi.org/10.1200/JCO.1997.15.3.963.
  • Startseva Zh.A., Simonov K.A., Slonimskaya E.M. Differentsirovannyi podkhod k naznacheniyu ad"yuvantnoi luchevoi terapii u bol'nykh operabel'nym rakom molochnoi zhelezy. Radiatsiya i risk. 2014; 23(2): 102-11.
  • Parijs V.H., Cecilia-Joseph E., Gorobets O., Storme G., Adriaenssens N., Heyndrickx B., Verschraegen C., Nguyen N.P., Ridder M.D., Vinh-Hung V. Lung-Heart. Lung-heart toxicity in a randomized clinical trial of hypofractionated image guided radiation therapy for breast cancer. Preprints. 2022; 1. https://doi.org/10.20944/preprints202212.0214.v1.
  • EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group; Bijker N., Meijnen P., Peterse J.L., Bogaerts J., Van Hoorebeeck I., Julien J.P., Gennaro M., Rouanet P., Avril A., Fentiman I.S., Bartelink H., Rutgers E.J. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006; 24(21): 3381-7. https://doi.org/10.1200/JCO.2006.06.1366.
  • Ortabaeva D.R., Zikiryakhodzhaev A.D., Rasskazova E.A., Saribekyan E.K., Kaprin A.D. Otdalennye onkologicheskie rezul'taty organosokhranyayushchego lecheniya bez posleoperatsionnoi luchevoi terapii u bol'nykh rannim rakom molochnoi zhelezy starshe 65 let. Opukholi zhenskoi reproduktivnoi sistemy. 2022; 18(3): 24-8. https://doi.org/10.17650/1994-4098-2022-18-3-24-28.
  • Liveringhouse C.L., Washington I.R., Diaz R., Jimenez R.B., Harris E.E., Rabinovitch R., Woodward W.A., Torres-Roca J.F., Ahmed K.A. Genomically guided breast radiation therapy: a review of the current data and future directions. Adv Radiat Oncol. 2021; 6(4). https://doi.org/10.1016/j.adro.2021.100731.
  • Chadha M., Ghiassi-Nejad Z., Cate S., Gillego A., Wallach J., Boolbol S.K. Oncotype score as a predictor of local-regional recurrence in early stage breast cancer (BC). Int J Rad Oncol Biol Phys. 2017; 99(2): 54-5. https://doi.org/10.1016/j.ijrobp.2017.06.137.
  • Allen S.G., Speers C., Jagsi R. Tailoring the Omission of Radiotherapy for Early-Stage Breast Cancer Based on Tumor Biology. Semin Radiat Oncol. 2022; 32(3): 198-206. https://doi.org/10.1016/j.semradonc.2022.01.006.
  • The IDEA Study [Internet]. (Individualized Decisions for Endocrine Therapy Alone) [cited 2022 Dec 1]. URL: https://clinicaltrials.gov/ct2/show/NCT02400190.
  • The PRECISION Trial [Internet] (Profling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer. [cited 2022 Dec 1]. URL: https://www.clinicaltrials.gov/ct2/show/NCT02653755.
  • Whelan T.J., Smith S., Nielsen T.O., Parpia S., Fyles A.W., Bane A., Liu F., Grimard L., Stevens C., Bowen J., Provencher S., Rakovitch E., Theberge V., Mulligan A.M., Akra M.A., Voduc K.D., Hijal T., Dayes I.S., Pond G.R., Levine M.N. LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC). J Clin Oncol. 2022; 40(17). https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA501.
  • De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) [Internet]. [cited 2022 Dec 1]. URL: https://www.clinicaltrials.gov/ct2/show/NCT04852887.
  • EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer (EXPERT) [Internet]. [cited 2022 Dec 1]. URL: https://clinicaltrials.gov/ct2/show/NCT02889874.
Еще
Статья обзорная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp